Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study

Authors

  • B. B. Samura Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2409-2932.2018.3.145251

Keywords:

galectin-3, chronic lymphocytic leukemia, cardiovascular events, risk factors

Abstract

Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission.

Materials and methods. One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected at the visit of inclusion into the study. ELISA method for measurements of circulating level of galectin-3 was used. Cardiovascular events were evaluated for 3 year observation period.

Results. Two hundred seventy cumulative clinical events occurred in 68 patients (43.3 %) within the follow-up, with their distribution being as follows: 12 deaths for cardiovascular reasons, 17 life-threatening arrhythmias, 36 cardiac ischemic events, 9 strokes, 38 decompensated chronic heart failures and 58 hospital admissions for cardiovascular reasons.

Mean levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.22 ± 3.06 ng/ml and 12.64 ± 5.24 ng/ml (Р < 0.0001). In patients after antitumor treatment with anthracyclines mean levels of galectin-3 were higher in comparing with patients after antitumor treatment without anthracyclines (Р = 0.0014). There were no differences in the value of galectin-3 in depend on gender, age, cumulative dose of anthracyclines, arterial hypertension, hyperlipidemia, diabetes mellitus, body mass index, smoking.

Conclusions. Among patients with chronic lymphocytic leukemia in remission increased circulating galectin-3 associates with presence of anthracyclines in antitumor treatment and increased cumulative cardiovascular events within 3 year observation period.

 

References

Kriachok, I. A. (2013) Khronicheskij limfolejkoz: novoe v lechenii. Podhody k terapii pervoj linii i ikh e'volyuciya [Chronic lymphocytic leukemia: new in treatment Approaches to the first-line treatment and their evolution]. Klinicheskaya onkologiya, 3, 121–129. [in Russian].

Samura, B. B., Kolesnik, Y. M., & Syvolap, V. V. (2014) Znachennia tsyrkuliuiuchoho halektynu-3 v prohnozuvannі kardіovaskuliarnykh podіi u patsіientіv іz khronіchnoiu lіmfotsytarnoiu leikemіieiu v remіsіi [Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission]. Zaporozhye medical journal, 6(86), 44–47. [in Ukrainian]. doi: https://doi.org/10.14739/2310-1210.2014.6.35662.

Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., et al. (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J. Clin. Oncol., 31(29), 3673–3680. doi: 10.1200/JCO.2013.49.3205.

Dumic, J., Dabelic, S., & Flögel, M. (2006) Galectin-3: an open-ended story. Biochim Biophys Acta., 1760(4), 616–35. doi: 10.1016/j.bbagen.2005.12.020.

Ewer, M. S., & Ewer, S. M. (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol., 12(9), 547–58. doi: 10.1038/nrcardio.2015.65.

FDA.510(k) Substantial equivalence determination decision summary. Review memorandum K093758. Retrieved from http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf.

Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., et al. (2003) Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest., 112(3), 389–97. doi: 10.1172/JCI17592.

Downloads

How to Cite

1.
Samura BB. Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study. Current issues in pharmacy and medicine: science and practice [Internet]. 2018Oct.24 [cited 2024Apr.19];(3). Available from: http://pharmed.zsmu.edu.ua/article/view/145251

Issue

No. 3 (2018)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)